<DOC>
	<DOCNO>NCT01993979</DOCNO>
	<brief_summary>POUT multi-centred randomise control phase III trial . 345 patient undergone nephro-ureterectomy , surgically stag pT2-pT4 , N0-3 pT1 node positive , fit adjuvant chemotherapy , randomise four cycle adjuvant platinum base chemotherapy ( experimental group ) surveillance ( control group ) . Participants follow accord routine practice . Primary endpoint : Disease-free survival ( DFS ) Secondary endpoint : - Overall Survival - Metastasis free survival - Incidence bladder second primary tumour - Incidence contralateral primary tumour - Acute late toxicity - Treatment compliance - Quality life</brief_summary>
	<brief_title>A Phase III Randomised Trial Peri-Operative Chemotherapy Versus sUrveillance Upper Tract Urothelial Cancer ( POUT )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Written inform consent ≥18 year age Post radical nephroureterectomy upper tract tumour predominant TCC component squamoid differentiation mixed TCC/SCC permit . Histologically confirm TCC stag pT2pT4 pN03 M0 pTany N13 M0 ( provide grossly abnormal node resect ) . Patients microscopically positive margin pathology may enter ( provide grossly abnormal disease resect ) . Satisfactory haematological profile ( ANC &gt; 1.5 x 109/L , platelet count ≥ 100 x 109/L ) liver function test ( bilirubin &lt; 1.5 x ULN , AST Alkaline phosphatase &lt; 2.5 x ULN ) , Glomerular filtration rate ≥30 mls/min . Fit willing receive adjuvant chemotherapy first cycle commence within 90 day radical nephroureterectomy allocate WHO performance status 01 . Available longterm followup Evidence distant metastasis Pure adenocarcinoma , squamous cell carcinoma small cell variant histology Unresected macroscopic nodal disease Concurrent muscle invasive bladder cancer ( patient concurrent Nonmuscle invasive bladder cancer ( NMIBC ) eligible ) GFR &lt; 30 ml/minute . NB Gemcitabinecarboplatin give patient suboptimal renal function cisplatin i.e . GFR 3049ml/min . Patients poor performance status comorbidities would make unfit chemotherapy ineligible trial Significant comorbid condition would interfere administration protocol treatment Pregnancy ; lactate woman woman childbearing potential unwilling unable use adequate nonhormonal contraception ( male patient also use contraception sexually active ) ; Previous malignancy last 5 year except previous NMIBC , adequately control non melanoma skin tumour , CIS cervix LCIS breast localise prostate cancer patient life expectancy 5 year upon trial entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Adjuvant chemotherapy</keyword>
	<keyword>Surveillance</keyword>
	<keyword>Nephro-ureterectomy</keyword>
</DOC>